Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Sodium Orthovanadate in Translational Signaling
2026-09-09
A mechanistic and strategic guide to using Sodium Orthovanadate and Na3VO4 for phosphorylation state preservation, insulin-signaling studies, kinase assays, and translational assay design.
O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia
2026-09-08
The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that connects protein modification with iron uptake, ferroptosis, and trophoblast syncytialization in preeclampsia. Its combination of O-GlcNAc modification proteomics, mechanistic validation, trophoblast models, and mouse experiments provides a framework for testing how placental stress is regulated.
Ceftolozane/Tazobactam: Mechanism, Evidence, and Limits
2026-09-08
The reference review presents ceftolozane/tazobactam as an engineered antipseudomonal cephalosporin–β-lactamase inhibitor combination designed to preserve activity against important resistant Gram-negative pathogens. Its key practical contribution is linking PBP pharmacology, β-lactamase coverage, pharmacokinetic/pharmacodynamic targets, renal dosing, and clinical-trial evidence into a framework for evaluating resistant-infection therapies.
Vernakalant Hydrochloride: AF Assay Workflows
2026-09-07
Vernakalant Hydrochloride supports translational studies that connect atrial ion-channel pharmacology with rapid conversion of atrial fibrillation. This guide presents exposure-aware cell assays, PK-linked interpretation, workflow controls, and troubleshooting strategies for RSD1235 research.
Ridaforolimus for mTOR Cancer Research
2026-09-07
Ridaforolimus, also called Deforolimus or MK-8669, gives researchers a nanomolar tool for connecting mTOR pathway inhibition with proliferation, protein synthesis, VEGF output, and treatment response. This guide translates its reported activity into practical cancer-cell workflows while showing how machine-learning-derived senolytic research can inform assay design without overstating the evidence.
Pexidartinib: From Microglia to Tumor Macrophages
2026-09-05
Pexidartinib (PLX3397) offers translational researchers a selective chemical entry point into CSF1R biology, connecting macrophage control in oncology with broader principles of myeloid regulation. This article interprets recent evidence on microglial activation and seizure susceptibility to define a disciplined strategy for tumor microenvironment studies, including experimental validation, competitive positioning, and translational limits.
Wnt agonist 1: Practical Pathway Activation
2026-09-04
Wnt agonist 1, also known as BML-284, provides a controllable small-molecule entry point for β-catenin/TCF signaling studies. This guide connects dose-response design, differentiation and developmental assays, and a hypothesis-driven cancer workflow to practical handling and troubleshooting decisions.
Rotenone: A Mechanistic Guide to Mitochondrial Stress
2026-09-04
Rotenone is a mitochondrial Complex I inhibitor used to model respiratory failure, oxidative stress, apoptosis, and neurodegeneration. This guide extends beyond routine protocols by connecting mitochondrial assay design with the compartment-specific immunometabolic insights reported in recent macrophage research.
EPI-001 and the Next Frontier of AR-Driven Oncology
2026-09-03
EPI-001 offers a mechanistically differentiated way to study androgen receptor signaling by targeting the receptor’s N-terminal domain. This article connects prostate cancer and TNBC evidence, outlines translational workflows, and explains how AR/ARv7 biology may guide future research decisions.
Candida EVs Repress Hyphae Through NRG1
2026-09-03
This study identifies a concentration- and time-dependent self-regulatory role for Candida albicans extracellular vesicles (EVs): accumulated EVs suppress hyphal development by activating the SKO1–NRG1 transcriptional axis and reducing hyphal gene expression. The same pathway was associated with improved survival and lower organ fungal burden in a mouse candidemia model, although the responsible EV cargo proteins and clinical relevance require further definition.
Ridaforolimus: mTOR Workflow for Cancer Research
2026-09-02
Ridaforolimus, also called Deforolimus or MK-8669, gives researchers a target-proximal way to connect mTOR signaling with proliferation, VEGF output, and stress phenotypes. This workflow combines dose-response profiling, phosphoprotein validation, apoptosis assay design, and senescence-aware controls without incorrectly labeling mTOR inhibition as senolysis.
THZ1 and the Transcription Quality-Control Gate
2026-09-02
THZ1 is a covalent CDK7 inhibitor that connects transcriptional control with cancer-cell vulnerability. This article interprets THZ1 through new RNA polymerase II quality-control findings, helping researchers design more discriminating transcription and apoptosis assays.
Biotin-16-UTP for Reliable RNA Mechanism Studies
2026-09-01
Learn how Biotin-16-UTP, SKU B8154, supports reproducible in vitro RNA labeling when proliferation, viability, or cytotoxicity results require mechanistic follow-up. This scenario-based guide covers compatibility, optimization, interpretation, and practical product-selection criteria.
GW 4869 for Exosome–Kidney Research
2026-09-01
GW 4869 provides a practical way to test whether neutral sphingomyelinase-dependent vesicle release contributes to podocyte–endothelial injury. This workflow translates lupus nephritis findings into controlled donor–recipient assays while emphasizing vehicle, viability, particle, and cargo controls.
LY294002: PI3K Signaling in Mechanistic Assays
2026-08-31
LY294002 is a reversible class I PI3K inhibitor for dissecting Akt/mTOR-dependent phenotypes. This article connects its pharmacology with microglial amyloid-β uptake assays, emphasizing causal controls, pathway timing, and limits of interpretation.
8050 records 9/537 page Previous Next First page 上5页 678910 下5页 Last page